Reactions 1704, p367 - 2 Jun 2018 Hyperbilirubinaemia: case report In a retrospective study of 200 patients, a patient [age and sex not stated] was described, who developed hyperbilirubinaemia during treatment with voriconazole. The patient, who had neutropenia and haematological malignancies, started receiving anti-fungal prophylaxis with oral voriconazole tablet 200mg twice a day. Subsequently, the patient developed hyperbilirubinaemia, and voriconazole was discontinued [duration of treatment to reaction onset and outcome not stated]. Author comment: "Eleven patients had to discontinue voriconazole. . .hyperbilirubinemia (one patient)". "Symptomatic adverse events were significantly more common in the voriconazole group." Hachem R, et al. Comparing the safety and efficacy of voriconazole versus posaconazole in the prevention of invasive fungal infections in high-risk patients with hematological malignancies. International Journal of Antimicrobial Agents 50: 384-388, No. 3, Sep 2017. Available from: URL: http://doi.org/10.1016/ j.ijantimicag.2017.03.021 - USA 803324029 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud